💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Canagliflozin

CHEMBL4594217 Phase 4 Approved Small molecule
Half-Life
10.6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
444.5 g/mol
LogP
3.2
Phase
4

An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.

Molecular Weight

444.5170 g/mol

LogP

3.20

TPSA

118.00 Ų

Lipinski RO5

Pass

Therapeutic Areas

Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Colorectal Cancer Gout Heart Failure HIV/AIDS Hypertension Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Ovarian Cancer Pancreatic Cancer Prostate Cancer Stroke Thyroid Cancer Type 2 Diabetes

Drug Classes

A — A - Alimentary Tract and Metabolism

Mechanism of Action

Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

Pharmacokinetics (PK)

Half-Life 10.6 hours

Pharmacodynamics (PD)

Mechanism

Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O

                

                

                
                

                    
InChI

                    
InChI=1S/C24H25FO5S.H2O/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14;/h2-10,19,21-24,26-29H,11-12H2,1H3;1H2/t19-,21-,22+,23-,24+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H25FO5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Rotatable Bonds

                        
5

                    

                    
                    
                    

                        
Heavy Atoms

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Canagliflozin: Half-life: 10.6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Canagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Dapagliflozin
                            Small molecule
                        
                        
                        
                            Dulaglutide
                            Protein
                        
                        
                        
                            Empagliflozin
                            Small molecule
                        
                        
                        
                            Esomeprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4594217.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24812758.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.